Rockefeller Capital Management
RNTX

Rockefeller Capital Management’s Rein Therapeutics RNTX Stock Holding History

Rockefeller Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.63K Hold
5,097
– – ﹤0.01% 4154
2025
Q4 		$5.91K Hold
5,097
– – ﹤0.01% 4014
2025
Q3 		$5.84K Buy
+5,097
New +$6.47K ﹤0.01% 3826
2023
Q1 		– Sell
-50
Closed – – 3962
2022
Q4 		$0 Hold
50
– – ﹤0.01% 4273
2022
Q3 		$0 Hold
50
– – ﹤0.01% 4459
2022
Q2 		$0 Hold
50
– – ﹤0.01% 4443
2022
Q1 		$0 Buy
+50
New +$453 ﹤0.01% 4100

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Rockefeller Capital Management's RNTX Position: Q1 2026 in Review

Rockefeller Capital Management held its Rein Therapeutics (RNTX) position steady in Q1 2026 at 5,097 shares worth $6.63K. The position accounts for ﹤0.01% of the portfolio, ranked #4154.

Rockefeller Capital Management first reported a position in RNTX in Q1 2022 and has held it in 7 quarters since. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Rockefeller Capital Management held 5,097 shares of Rein Therapeutics worth $6.63K as of Q1 2026.
  • Rockefeller Capital Management left its Rein Therapeutics share count unchanged in Q1 2026.
  • Rein Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4154 holding.
  • Rockefeller Capital Management first reported a position in Rein Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.